| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/20/2000 | WO2000042035A1 4-(heterocyclylsulfonamido) -5-methoxy-6- (2-methoxyphenoxy) -2-phenyl- or pyridylpyrimidines as endothelin receptor antagonists |
| 07/20/2000 | WO2000042031A2 Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| 07/20/2000 | WO2000042029A1 1-heterocycle substituted diarylamines |
| 07/20/2000 | WO2000042023A1 Substituted imidazoles, their preparation and use |
| 07/20/2000 | WO2000042022A1 Benzoheterocycles and their use as mek inhibitors |
| 07/20/2000 | WO2000042003A1 Benzenesulfonamide derivatives and their use as mek inhibitors |
| 07/20/2000 | WO2000042002A1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
| 07/20/2000 | WO2000041994A1 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| 07/20/2000 | WO2000041992A1 Reductive alkylation of secondary amines with hydrosilane |
| 07/20/2000 | WO2000041740A2 Particles for oral delivery of peptides and proteins |
| 07/20/2000 | WO2000041730A1 A composition and method for the enhancement of the efficacy of drugs |
| 07/20/2000 | WO2000041727A1 Transcutaneous photodynamic treatment of targeted cells |
| 07/20/2000 | WO2000041726A2 Noninvasive vascular therapy |
| 07/20/2000 | WO2000041722A1 Use of antibodies for anticancer vaccination |
| 07/20/2000 | WO2000041717A2 Chorionic gonadotropin dna vaccines and methods |
| 07/20/2000 | WO2000041707A2 USE OF $i(LACTOBACILLUS SALIVARIUS) |
| 07/20/2000 | WO2000041706A1 Pro-apoptotic agents |
| 07/20/2000 | WO2000041696A1 Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances |
| 07/20/2000 | WO2000041689A1 Telomerase inhibitors |
| 07/20/2000 | WO2000041687A2 Composition and methods for administration of water-insoluble paclitaxel derivatives |
| 07/20/2000 | WO2000041678A1 Methods for treating ovarian cancer, poly(phosphoester) compositions, and biodegradable articles for same |
| 07/20/2000 | WO2000041669A2 Benzimidazole vascular damaging agents |
| 07/20/2000 | WO2000041566A1 Regulation of endogenous gene expression in cells using zinc finger proteins |
| 07/20/2000 | WO2000041548A2 Methods for glucagon suppression |
| 07/20/2000 | WO2000041545A2 Regulators of the pct or smoothened pathway, compositions and uses related thereto |
| 07/20/2000 | WO2000041516A2 Reagents and methods useful for detecting diseases of the breast |
| 07/20/2000 | WO2000041508A2 Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines |
| 07/20/2000 | WO2000041505A2 Anthranilic acid derivatives |
| 07/20/2000 | WO2000041482A2 Oral administration of taxoid derivatives |
| 07/20/2000 | WO2000041469A2 β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS |
| 07/20/2000 | WO2000024885A3 p53 MORPHOLINO-BASED ANTISENSE |
| 07/20/2000 | WO2000021979A3 Cyclic tetrapeptide and their use as histone deacetylase inhibitor |
| 07/20/2000 | WO2000021521A3 Sertraline oral concentrate |
| 07/20/2000 | WO2000020590A3 G-protein coupled receptor proteins |
| 07/20/2000 | WO2000020041A3 Removal of preexisting antibodies to enhance the effectiveness of a therapeutic viral immunogenic agent |
| 07/20/2000 | WO2000017358A3 Human chaperone proteins |
| 07/20/2000 | WO2000015246A3 Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto |
| 07/20/2000 | WO2000015203A3 Use of methoxymorpholino doxorubicin for the treatment of a liver tumor |
| 07/20/2000 | WO2000015176A3 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
| 07/20/2000 | WO2000004149A3 Compositions and methods for therapy and diagnosis of prostate cancer |
| 07/20/2000 | WO2000003709A9 Novel dna-cleaving antitumor agents |
| 07/20/2000 | WO2000002902A9 Novel inhibitors of angiogenesis and tumor growth |
| 07/20/2000 | WO2000002897A9 Delta cleavage products and methods based thereon |
| 07/20/2000 | WO2000000514A9 Synthetic spiroketal pyranes as potent anti-cancer agents |
| 07/20/2000 | WO1999054353A3 Human nucleic acid sequences of normal uterus tissue |
| 07/20/2000 | DE19901009A1 Peptide zur Inhibierung von HBV-Core-Proteinen Peptides to inhibit HBV core proteins |
| 07/20/2000 | DE19901008A1 Peptide zur Inhibierung von HPV E6-Proteinen Peptides for inhibition of HPV-E6 proteins |
| 07/20/2000 | CA2724287A1 Bifidobacterium in the treatment of inflammatory disease |
| 07/20/2000 | CA2697598A1 Compounds and methods to inhibit or augment an inflammatory response |
| 07/20/2000 | CA2370042A1 Regulators of the pct or smoothened pathway, compositions and uses related thereto |
| 07/20/2000 | CA2360588A1 Human homologues of proteins regulated by circadian rhythms |
| 07/20/2000 | CA2360581A1 A novel method for designing protein kinase inhibitors |
| 07/20/2000 | CA2360563A1 Novel interferon-.alpha. |
| 07/20/2000 | CA2360464A1 Human peptidases |
| 07/20/2000 | CA2360356A1 .beta.-phenylalanine derivatives as integrin antagonists |
| 07/20/2000 | CA2360243A1 Use of lactobacillus salivarius |
| 07/20/2000 | CA2360232A1 Telomerase inhibitors |
| 07/20/2000 | CA2359795A1 Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use |
| 07/20/2000 | CA2359569A1 Reductive alkylation of secondary amines with hydrosilane |
| 07/20/2000 | CA2359562A1 Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| 07/20/2000 | CA2359479A1 Novel complex-forming proteins |
| 07/20/2000 | CA2359474A1 Particles for oral delivery of peptides and proteins |
| 07/20/2000 | CA2359067A1 Polypeptide variants with altered effector function |
| 07/20/2000 | CA2358748A1 Reagents and methods useful for detecting diseases of the breast |
| 07/20/2000 | CA2358684A1 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
| 07/20/2000 | CA2358638A1 Composition and methods for administration of water-insoluble paclitaxel derivatives |
| 07/20/2000 | CA2357726A1 Chorionic gonadotropin dna vaccines and methods |
| 07/20/2000 | CA2356776A1 Transcutaneous photodynamic treatment of targeted cells |
| 07/20/2000 | CA2356532A1 Noninvasive vascular therapy |
| 07/20/2000 | CA2355374A1 1-heterocycle substituted diarylamines |
| 07/20/2000 | CA2349832A1 Benzenesulfonamide derivatives and their use as mek inhibitors |
| 07/20/2000 | CA2349467A1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
| 07/20/2000 | CA2349180A1 Anthranilic acid derivatives |
| 07/20/2000 | CA2348236A1 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| 07/20/2000 | CA2325359A1 Novel lrsg protein and nucleic acid molecules and uses therefor |
| 07/19/2000 | EP1020519A1 Minor histocompatibility antigens and their use in the diagnosis and treatment of tumors |
| 07/19/2000 | EP1020471A1 Process for producing UCN-01 |
| 07/19/2000 | EP1020462A1 Heterocyclic compounds and antitumor agent containing the same as active ingredient |
| 07/19/2000 | EP1020188A1 New use of taxoid derivatives |
| 07/19/2000 | EP1019728A1 Method of activating a novel ligand regulatory pathway |
| 07/19/2000 | EP1019530A1 A method of treating cancer |
| 07/19/2000 | EP1019529A1 A method of treating cancer |
| 07/19/2000 | EP1019518A1 Self-deleting vectors for cancer therapy |
| 07/19/2000 | EP1019515A1 Fusion proteins comprising an angiostatin moiety and their use in anti-tumour treatment |
| 07/19/2000 | EP1019506A1 101 human secreted proteins |
| 07/19/2000 | EP1019500A2 Novel ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons |
| 07/19/2000 | EP1019499A2 Methods and compositions for inducing tumor-specific cytotoxicity |
| 07/19/2000 | EP1019438A1 Apoptosis-related compounds and their use |
| 07/19/2000 | EP1019434A2 Inhibitors of metalloproteinases, their therapeutic use, and process for the production of the starting compound in their synthesis |
| 07/19/2000 | EP1019427A1 N?6 -substituted-adenosine-5'-uronamides as adenosine receptor modulators |
| 07/19/2000 | EP1019409A1 Poly(adp-ribose) polymerase ("parp") inhibitors, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| 07/19/2000 | EP1019400A1 Benzo(5,6)cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors |
| 07/19/2000 | EP1019398A1 Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives useful for inhibition of farnesyl protein transferase |
| 07/19/2000 | EP1019395A1 Farnesyl transferase inhibiting 2-quinolone derivatives |
| 07/19/2000 | EP1019392A1 Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases |
| 07/19/2000 | EP1019391A1 Inhibitors of prenyl-protein transferase |
| 07/19/2000 | EP1019389A2 Epothilone derivatives |
| 07/19/2000 | EP1019386A1 Reverse hydroxamate derivatives as metalloprotease inhibitors |
| 07/19/2000 | EP1019369A1 Thio derivatives as naaladase inhibitors |
| 07/19/2000 | EP1019091A1 50 human secreted proteins |